

20 August 2025

Coagulation Factors

How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in (January, February, March, April, May and June 2025)?

1. With BPA/Hemlibra Inhibitor?

2. Please fill in the BPA/Hemlibra products *utilized* in January, February, March, April, May and June 2025)?

January through June 2025		Volume (IU)/mg	Total Patients	Patients	
				Prophylaxis	On demand
	<i>Example: FEIBA</i>	<i>50,000 IU</i>	<i>1</i>	<i>0</i>	<i>0</i>
Hem A Inhibitor Patients					
Haem A Inhibitor Patients	FEIBA				
	Cevenfacta				
	NovoSeven				
	Hemlibra				
Haem B Inhibitor Patients	FEIBA				
	Cevenfacta				
	NovoSeven				
	Obizur				
AHA Patients					
AHA Patients	FEIBA				
	NovoSeven				
	Obizur				
	Cevenfacta				
	Hemlibra				
Other Use					
FVII deficient	NovoSeven				
Glanzmann's	NovoSeven				
Other	NovoSeven				
Other	Cevenfacta				

3. How many minor and major surgeries did your BPA patients have in January, February, March, April, May and June 2025)??

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries

20 August 2025

NovoSeven				
FEIBA				
Obizur				

4. How many minor and major surgeries did your BPA/Hemlibra inhibitor patients have in January, February, March, April, May and June 2025)?

	Inhibitor patients		Glanzmann, FVII deficiency, AHA	
	Minor surgeries	Major surgeries	Minor surgeries	Major surgeries
NovoSeven				
FEIBA				
Obizur				

5. How many breakthrough bleeds did your Hemlibra Inhibitor patients have, and what brand were they treated with?

	Inhibitor patients	January, February, March, April, May and June 2025) volume (IU/mg)
Hemlibra		
NovoSeven		
FEIBA		

6. Were there any changes in the total number of acute bleeds treated with factor in Q2'25 (April-June 2025) compared to Q1'25 (Jan-Mar 2025)
 If yes, please specify whether there was an increase, decrease, or no change, and provide actual numbers if available

7. Was there any change in the number of elective surgeries using factor in Q2'25 compared to Q1'25?
 Please specify the number of surgeries in both quarters and clarify if there was an increase, decrease, or no change

<i>Number of Surgeries</i>	<i>BPA</i>
Increase / Decrease / Stable compared to Q1'25?	
How many surgeries occurred in Q2'25?	

20 August 2025

8. Have any BPA patients switched products between January 1st through June 2025? What were the reasons for the switches?

Indication	Previous Medication	Previous Regimen	Current Medication	Current Regimen	Severity of patient	Reason
<i>Example: Haem B Inh.</i>	<i>1 NovoSeven</i>	<i>On-demand</i>	<i>Cevenfacta</i>	<i>Prophy 1x/week</i>	<i>Severe</i>	<i>Patient requested to try out a new product to improve treatment</i>

9. What is the total number of patients treated with NovoSeven at Belfast Health and Social Care Trust for each month (January–June 2025)?
 Question

The information requested in Questions 1 to 9 above, is exempt under Section 21 - Information accessible to applicant by other means.

The information requested is readily available from the National Haemophilia Database (NHD).

Belfast Health and Social Care Trust supplies treatment in line with the National Framework and reports all diagnosis, treatments and regimes, on a quarterly basis, to the National Haemophilia Database provided by the UKHCDO.

Any individual / company can apply to the National Haemophilia Database for this information.

[NHD – UKHCDO](#)

20 August 2025